Insomnia Market Size, Share, Key Players, Trends & Forecast 2025-2033

Global Insomnia Industry: Key Statistics and Insights in 2025-2033

Summary:

• • The global insomnia market size reached USD 5.3 Billion in 2024.

• • The market is expected to reach USD 6.8 Billion by 2033, exhibiting a growth rate (CAGR) of 2.55% during 2025-2033.

• • North America's leads the market, accounting for the largest insomnia market share.

• • Benzodiazepines dominate the market due to their long history of use and proven effectiveness in helping people fall asleep.

• • The market is split into four main groups for selling: hospitals with pharmacies, pharmacies you can visit, drugstores, and pharmacies on the internet.

• • Insomnia is more common in older adults. As people age, their sleep habits change. They often experience lighter sleep and wake up more frequently at night. Many also find themselves waking up earlier in the morning.

• • Advances in technology are enabling the development of digital solutions to treat insomnia.

Industry Trends and Drivers:

• • Increasing Aging Population:

Insomnia is becoming more common as people are aging. Older adults often have changes in their sleep patterns, such as sleeping more lightly, waking up more often during the night, and waking up earlier in the morning. This means that insomnia is more common in older people than in younger age groups. As people age, they often develop or see a worsening of certain medical conditions, including chronic pain, arthritis, respiratory problems, and neurological disorders like Parkinson's disease and dementia. These comorbidities can make insomnia worse or even cause it, which can lead older adults to seek help for their sleep issues.

• • Technological Advancements:

Innovations in technology are leading to the development of digital health solutions for insomnia management. Mobile applications, wearable devices, and online platforms offer various tools and resources for tracking sleep patterns, implementing cognitive behavioral therapy for insomnia (CBT-I) techniques, and monitoring progress over time. These digital tools provide individuals with convenient and accessible options for managing their sleep disorders, thereby expanding the reach of insomnia treatments. Furthermore, advancements in telemedicine technologies allow healthcare providers to assess and monitor patients with insomnia remotely. Virtual consultations, remote monitoring tools, and telehealth platforms enable individuals to receive personalized sleep assessments, access evidence-based treatments, and receive ongoing support from healthcare professionals without the need for in-person visits.

• • Rising Healthcare Expenditure:

As healthcare spending is increasing, the investment in research and development (R&D) activities in the pharmaceutical and medical industries is rising. Pharmaceutical companies and device manufacturers are allocating resources to develop new insomnia treatments, innovative therapies, and advanced diagnostic tools. This R&D investment leads to the discovery of novel drugs, formulations, and technologies for managing insomnia more effectively, thereby expanding the range of treatment options available in the market. In addition, rising healthcare expenditures often translates into the expansion and modernization of healthcare infrastructure, including hospitals, clinics, sleep centers, and outpatient facilities. The availability of state-of-the-art diagnostic equipment, sleep laboratories, and specialized sleep clinics enables healthcare providers to offer comprehensive sleep evaluation and management services to patients with insomnia.

Grab a sample PDF of this report: https://www.imarcgroup.com/insomnia-market/requestsample

Insomnia Market Report Segmentation:

By Drug Class:

• • Antidepressants

• • Melatonin Antagonist

• • Benzodiazepines

• • Nonbenzodiazepines

• • Orexin Antagonist

• • Others

Benzodiazepines account for the majority of the market share owing to their long-standing history of use and established efficacy in promoting sleep.

By Distribution Channel:

• • Hospital Pharmacies

• • Retail Pharmacies

• • Drug Stores

• • Online Pharmacies

Based on the distribution channel, the market has been divided into hospital pharmacies, retail pharmacies, drug stores, and online pharmacies.

Regional Insights:

• • North America (United States, Canada)

• • Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)

• • Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)

• • Latin America (Brazil, Mexico, Others)

• • Middle East and Africa

North America enjoys the leading position in the insomnia market on account of advanced healthcare infrastructure and a robust network of healthcare providers specializing in sleep medicine.

Top Insomnia Market Leaders:

The insomnia market research report outlines a detailed analysis of the competitive landscape, offering in-depth profiles of major companies. Some of the key players in the market are:

• • Astellas Pharma Inc.

• • Aurobindo Pharma Limited

• • Biocodex

• • Eisai Co. Ltd.

• • Mallinckrodt Pharmaceuticals

• • Merck & Co. Inc.

• • Neurim Pharmaceuticals Inc.

• • Pfizer Inc.

• • Sanofi S.A.

• • Sumitomo Dainippon Pharma Co. Ltd. (Sumitomo Chemical Co. Ltd.)

• • Takeda Pharmaceutical Company Limited

• • Vanda Pharmaceuticals Inc.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145